Regeneron pharmaceuticals, inc. (REGN)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Cash flows from operating activities:
Net Income (Loss) Attributable to Parent

2,115,800

2,444,400

1,198,500

895,500

636,056

338,126

413,738

750,269

-221,760

-104,468

-67,830

-79,129

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization

210,300

148,200

145,500

104,700

74,909

52,686

41,204

36,940

31,082

19,687

14,247

11,287

Non-cash compensation expense

464,300

427,400

507,300

559,900

459,049

321,750

215,377

94,157

56,094

39,897

31,259

32,523

Other non-cash items, net

29,300

-12,100

-63,500

-45,100

-52,562

-77,571

-46,751

-34,049

-6,714

-4,037

-2,238

-

Non-cash interest expense

-

-

-

-

-

-

-

22,925

5,101

43

-

-

Loss on Extinguishment of Debt

-

-

-

-

-

-

0

0

-

-

-

-938

Net realized loss (gain) on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-1,310

Deferred taxes

130,600

140,000

-318,800

360,100

121,623

53,276

-62,195

340,156

0

0

-

-

Changes in assets and liabilities:
Increase in Sanofi, trade, and other accounts receivable

473,100

268,900

362,700

143,800

491,421

34,927

245,472

588,398

21,118

17,518

30,494

16,892

Increase in inventories

335,500

387,900

314,200

149,800

111,825

56,947

47,956

28,932

14,094

-

-

-

Decrease in prepaid expenses and other assets

130,400

55,700

113,300

-36,100

79,476

45,327

-7,571

25,371

-6,612

8,212

4,436

6,560

Increase in deferred revenue

294,000

-194,500

-113,100

244,300

608,892

-8,403

-41,496

-41,077

-40,329

158,151

-27,497

-26,834

(Decrease) increase in accounts payable, accrued expenses, and other liabilities

444,500

210,000

-23,200

254,000

303,657

161,182

136,684

10,979

50,016

7,605

12,577

-5,729

Total adjustments

314,200

-249,300

108,600

590,400

694,724

414,309

174,858

-824,884

80,078

203,690

-2,106

-9,957

Net cash provided by operating activities

2,430,000

2,195,100

1,307,100

1,485,900

1,330,780

752,435

588,596

-74,615

-141,682

99,222

-69,936

-89,086

Cash flows from investing activities:
Purchases of marketable and other securities

3,202,400

1,845,500

1,277,200

809,400

557,105

564,188

577,278

470,945

240,391

605,124

199,997

581,139

Sales or maturities of marketable securities

1,604,200

775,600

544,600

274,500

327,437

476,417

378,146

439,209

426,356

273,723

295,117

646,861

Purchase of restricted cash and marketable securities

-

-

-

-

-

-

-

-

277

5,941

-50

0

Capital expenditures

429,600

383,100

272,600

511,900

677,933

333,006

156,323

49,337

57,217

99,689

97,318

34,857

Other

0

10,000

0

0

-

-

-

-

-

-

-

-

Increase in restricted cash

-

-

-

-

-

-

-

-

-

-

-

50

Net cash used in investing activities

-2,027,800

-1,463,000

-1,005,200

-1,046,800

-907,601

-420,777

-355,455

-81,073

128,471

-437,031

-2,148

30,815

Cash flows from financing activities:
Proceeds in connection with capital and facility lease obligations

-

-

-

5,100

27,373

-1,095

-2,024

-

-

-

-

0

Payments in connection with capital and facility lease obligations

-

0

19,900

32,800

1,353

-

-

2,203

1,667

1,028

0

0

Proceeds in connection with finance lease liabilities

-

0

57,000

-

-

-

-

-

-

47,544

23,640

-

Payments in connection with facility lease obligation

-

-

-

-

-

-

-

-

-

-

875

0

Repayments of Convertible Debt

-

-

-

12,900

166,467

220,639

0

0

-

-

-

-

Payments for Repurchase of Warrants

-

-

-

643,400

573,487

294,552

0

0

-

-

-

-

Repurchases or repayment of notes payable

-

-

-

-

-

-

-

-

-

-

-

-200,807

Proceeds from issuance of Common Stock

211,800

114,500

240,200

126,700

206,358

126,045

57,393

63,549

43,587

200,588

8,598

7,949

Payments in connection with Common Stock tendered for employee tax obligations

188,000

187,200

301,700

143,200

160,537

267,584

195,087

163,300

25,078

3,798

-

-

Repurchases of Common Stock

275,900

4,400

0

0

-

-

-

-

-

-

-

-

Excess Tax Benefit from Share-based compensation

-

-

-

-

405,317

439,278

211,909

4,308

0

0

-

-

Proceeds in connection with issuance of convertible notes, net of debt issuance costs

-

-

-

-

-

-

-

-

391,107

0

0

-

Proceeds in connection with issuance of warrants

-

-

-

-

-

-

-

-

93,800

0

0

-

Payment in connection with purchase of convertible note hedges

-

-

-

-

-

-

-

-

117,500

0

0

-

Net cash provided by financing activities

-252,100

-77,100

-24,400

-700,500

-262,796

-218,547

72,191

-97,646

384,249

243,306

31,363

-192,858

Net increase in cash, cash equivalents, and restricted cash

150,100

655,000

277,500

-261,400

160,383

113,111

305,332

-253,334

371,038

-94,503

-40,721

-251,129

Supplemental Cash Flow Information [Abstract]
Cash paid for interest (net of amounts capitalized)

25,000

22,300

18,700

5,500

10,582

20,348

23,197

21,946

14,725

12,737

2,525

9,348

Cash paid for income taxes

342,300

205,600

754,800

481,400

276,092

59,847

1,057

0

-

-

-

3,079